{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79","upperLimit":"96","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Percentage of patients free from disease progression after 5 years from study entry","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate: Weeks 1-15:\n\n* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days\n* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle\n* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\\&5 of R-CHOP\n\nWeeks 18-22:\n\n• Methotrexate 1.5 g/m2 q14 Days x 2\n\nFrom Week 24:\n\n• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)","id":"OG000","title":"R-CHOP, Depocyte, Methotrexate"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From study entry until 5 years after","title":"5 Years Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}